March 18 (Reuters) - MetaVia Inc MTVA.O:
METAVIA ADVANCES GLP-1-BASED OBESITY PROGRAM WITH IRB APPROVAL FOR HIGHER-DOSE PHASE 1 STUDIES OF DA-1726, A GLP-1 AND GLUCAGON DUAL AGONIST DEMONSTRATING BEST-IN-CLASS POTENTIAL FOR WEIGHT LOSS AND GLUCOSE CONTROL